Zacks Research Brokers Decrease Earnings Estimates for ESPR

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Research analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a note issued to investors on Tuesday, March 25th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of ($0.19) for the quarter, down from their prior forecast of ($0.18). The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at $0.03 EPS, FY2025 earnings at ($0.36) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.03) EPS and FY2026 earnings at ($0.43) EPS.

Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Thursday, March 20th. The Goldman Sachs Group began coverage on Esperion Therapeutics in a research report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective for the company. Finally, JMP Securities restated a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $6.75.

Esperion Therapeutics Price Performance

Shares of ESPR stock opened at $1.50 on Friday. The stock has a market capitalization of $296.77 million, a PE ratio of -2.34 and a beta of 1.04. The business’s 50 day simple moving average is $1.78 and its 200 day simple moving average is $2.07. Esperion Therapeutics has a one year low of $1.47 and a one year high of $3.94.

Hedge Funds Weigh In On Esperion Therapeutics

Institutional investors have recently made changes to their positions in the stock. Cibc World Markets Corp bought a new stake in Esperion Therapeutics in the 4th quarter valued at about $39,000. SJS Investment Consulting Inc. acquired a new stake in Esperion Therapeutics in the fourth quarter valued at approximately $55,000. Crestline Management LP bought a new stake in shares of Esperion Therapeutics during the fourth quarter valued at approximately $63,000. Foundations Investment Advisors LLC increased its holdings in shares of Esperion Therapeutics by 48.6% during the fourth quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 9,872 shares in the last quarter. Finally, J.W. Cole Advisors Inc. acquired a new position in shares of Esperion Therapeutics during the fourth quarter worth approximately $66,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.